{"url_path":"/sec/ino/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001055726-26-000018-index.html","accession_number":"0001055726-26-000018","cik":"0001055726","ticker":"INO","issuer_name":"INOVIO PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001055726-26-000018-index.html","primary_entity_key":"0001055726","primary_entity_name":"INOVIO PHARMACEUTICALS, INC."},"word_count":462,"has_tables":true,"body_markdown":"ITEM 6.    EXHIBITS\n\n(a)    Exhibits\n\n58\n\n[Table of Contents](#ic1e691040a374fefb7d799d22dfe0d2c_7)\n\nExhibit\n\nNumber\nDescription of Document\n\n[3.1](https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm)\n\n[Certificate of Incorporation with all amendments prior to December 31, 2023 (incorporated by reference to Exhibit 3.1 to the registrant’s registration statement on Form S-3, filed on July 23, 2014).](https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm)\n\n[3.2](https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524015380/d736726d8k.htm)\n\n[Certificate of Amendment to Certificate of Incorporation, effective as of January 24, 2024 (incorporated by reference to Exhibit 3.1 to the registrant’s current report on Form 8-K filed on January 25, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524015380/d736726d8k.htm)\n\n[3.3](https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm)\n\n[Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August 10, 2011 (incorporated by reference to Exhibit 3.2 to the registrant’s current report on Form 8-K filed on August 12, 2011).](https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm)\n\n[4.1](https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120dex41.htm)\n\n[Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K filed on April 6, 2026).](https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120dex41.htm)\n\n[4.2](https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120dex42.htm)\n\n[Form of Series A Warrant (incorporated by reference to Exhibit 4.2 of the Registrant’s Current Report on Form 8-K filed on April 6, 2026).](https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120dex42.htm)\n\n[4.3](https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120dex43.htm)\n\n[Form of Series B Warrant (incorporated by reference to Exhibit 4.3 of the Registrant’s Current Report on Form 8-K filed on April 6, 2026).](https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120dex43.htm)\n\n[31.1](ino-33126x10qex311.htm)\n\n[Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)](ino-33126x10qex311.htm).\n\n[31.2](ino-3312610qex312.htm)\n\n[Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).](ino-3312610qex312.htm)\n\n[32.1](ino-33126x10qex321.htm) *\n\n[Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).](ino-33126x10qex321.htm)\n\n101.INSXBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).\n\n101.SCHInline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents.\n\n104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n*\nThis exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.\n\n59\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\nInovio Pharmaceuticals, Inc.\n\nDate:May 13, 2026By/s/    JACQUELINE E. SHEA      \n\nJacqueline E. Shea\n\nPresident, Chief Executive Officer and Director (On Behalf of the Registrant)\n\nDate:May 13, 2026By/s/    PETER KIES      \n\nPeter Kies\n\nChief Financial Officer (Principal Financial and Accounting Officer)\n\n60"}